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Summary
Medicare, the nationwide health insurance program for the aged and disabled,
does not cover most outpatient prescription drugs.  The absence of an adequate
prescription drug benefit has been of concern to policymakers since the enactment
of Medicare in 1965.  On several occasions, the Congress has considered providing
coverage for at least a portion of beneficiaries’ drug costs.  The issue has again
received attention this year.
There are a number of issues driving the prescription drug debate.  One of the
key concerns in designing a drug benefit is the potential cost and how costs would
increase over time.  Another issue is the appropriate role of both the federal
government and the private sector in assuming the financial risk of coverage and
administering the benefit.  Some observers suggest that a single uniform drug benefit
should be added directly to Medicare’s other benefits.  Others recommend offering
benefits through private plans which could offer different  benefit packages provided
certain minimum standards were met.  A further consideration is whether a major
new benefit should be added until structural reforms are made to the Medicare
program as a whole. 
 On June 28, 2002, the House passed the Medicare Modernization and
Prescription Drug Act of 2002 (H.R. 4954).  Under the bill, a new optional benefit
would be established, effective January 1, 2005.  The program would rely on private
plans to provide drug coverage and to bear some of the financial risk for drug costs;
federal subsidies would be provided to encourage participation.  Coverage would be
provided through prescription drug plans (PDPs) or Medicare+Choice (M+C) plans.
Beneficiaries could purchase either a standard plan or an actuarially equivalent plan.
Low-income subsidies would be provided for persons with incomes below 175% of
poverty.  A new Medicare Benefits Administration (MBA) would be established
within the Department of Health and Human Services (HHS) to administer the
benefit and the M+C program. 
In July 2002, the Senate considered and passed the Greater Access to Affordable
Pharmaceuticals Act (S. 812, Schumer et al).  Most of the debate on that measure was
devoted to consideration of several Medicare prescription drug amendments;
however, none of these amendments was able to garner the necessary votes. Several
key issues drove the debate.  These included whether the benefit should be
administered as part of the current Medicare program or by private entities, the
degree of financial risk that should be assumed by the federal government, and what
the benefit structure should look like and whether it should be the same nationwide.
A number of Senators have indicated their interest in revisiting the prescription drug
issue when the Congress reconvenes in September. This report will be updated to
reflect any further legislative action.
Contents
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Legislation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
Overview of Major Proposals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Scope of Benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Private vs. Public Sector Responsibility . . . . . . . . . . . . . . . . . . . . . . . . 3
Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Low-Income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Summary of Major Proposals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Side-by-Side Comparison of Major Medicare Drug Provisions of Selected Bills . 7
In General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Program Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Administration; Financial Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Pricing; Cost Controls . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Requirements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Low-Income Subsidies for Part D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Relationship to Other Coverage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Drug Card . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
1 For a discussion of the major issues that would need to be addressed as Congress considers
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Medicare: Major Prescription Drug 
Provisions of Selected Bills
Introduction
Medicare, the nationwide health insurance program for the aged and disabled,
does not cover most outpatient prescription drugs.  The absence of an adequate
prescription drug benefit has been of concern to policymakers since the enactment
of Medicare in 1965.  On several occasions, the Congress has considered providing
coverage for at least a portion of beneficiaries’ drug costs.  
The issue has again received attention this year.  On June 28, 2002, the House
passed the Medicare Modernization and Prescription Drug Act of 2002 (H.R. 4954)
by a vote of 221-208.  In July 2002, the Senate considered and passed the Greater
Access to Affordable Pharmaceuticals Act (S. 812, Schumer et al).  Most of the
debate on that measure was devoted to consideration of several Medicare prescription
drug amendments; however none of these amendments was able to garner the
necessary votes. 
There are a number of issues driving the prescription drug debate.  One of the
key concerns in designing a drug benefit is the potential cost and how costs would
increase over time.  Another issue is the appropriate role of both the federal
government and the private sector in assuming the financial risk of coverage and
administering the benefit.  Some observers suggest that a single uniform drug benefit
should be added directly to Medicare’s other benefits.  Others recommend offering
benefits through private plans which could offer different  benefit packages provided
certain minimum standards were met.  A further consideration is whether a major
new benefit should be added until structural reforms are made to the Medicare
program as a whole.1
It is generally agreed that if Congress were to enact a drug benefit this year, it
would take several years before the program could actually be implemented.  As an
interim measure, President Bush announced June 14, 2001, the creation of a
Medicare Prescription Drug Discount program.  This program would provide for the
endorsement by Medicare of qualified privately-administered prescription drug
discount cards.  Beneficiaries could obtain these cards either free or for a nominal
enrollment charge; the card would provide access to discounts on prescription drugs.
While this plan would not establish a Medicare drug benefit, it was intended to give
seniors access to similar kinds of discounts as are available to the under age 65
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2 For a discussion of the card program, see:  1) CRS Report RL31316, President Bush’s
Proposed Medicare-Endorsed Drug Discount Card Program:  Status and Issues, by M.
Angeles Villarreal; and 2) CRS Congressional Distribution Memorandum, Medicare-
Endorsed Prescription Drug Card Assistance Initiative – Summary of Proposed
Regulations, by Jennifer O’Sullivan, March 13, 2002.
population under private insurance plans.  However, to date, implementation of the
card program has been held up by court action.2
Legislation
A number of bills have been introduced in the 107th Congress which would
establish a prescription drug benefit for Medicare beneficiaries.  Some measures add
a new benefit to the Medicare program itself while others would provide the benefit
through private entities.  Some other bills focus on the prices seniors pay for drugs.
As of this writing, a few measures are receiving the most attention.  The first is
the House-passed bill,  the Medicare Modernization and Prescription Drug Act of
2002 (H.R. 4954).  The second bill is the Medicare Rx Drug Benefit and Discount
Act of 2002 (H.R.5019); this measure is commonly referred to as the House
Democratic bill. The rule governing debate on H.R. 4954 did not allow for
consideration of the Democratic bill.  This was because the measure exceeded the 10-
year (2003-2012) House-passed budget resolution figure of $350 billion for
prescription drugs and Medicare modernization. 
On July 15, 2002, the Senate began consideration of drug legislation. The Senate
used as the basis for the debate, the Greater Access to Affordable Pharmaceuticals
Act of 2001 (S. 812 Schumer et al.), reported by the Senate Committee on Health,
Education, Labor and Pensions (HELP) Committee on July 11, 2002.  The Senate
Finance Committee, which has jurisdiction over Medicare legislation, had not
reported a Medicare drug bill; however, several Medicare measures were considered
as amendments during the debate.  These included the Medicare Outpatient
Prescription Drug Act of 2002 (S.Amdt. 4309 to S. 812, Graham et al.), the Medicare
Prescription Drug Cost Protection Act of 2002 (S.Amdt. 4345, also known as the
Graham-Smith amendment), and the 21st Century Medicare Act (S. 2729, Grassley
et al.), sometimes referred to as the “tripartisan bill.”  The “tripartisan bill” has also
been introduced as S. 2 and S.Amdt. 4310 to S. 812.  All of the measures failed to
garner the necessary 60 votes to override a budget point-of-order. 
There are major differences among the House and Senate bills in the scope of
benefits, how the benefit would be administered, the degree of financial risk assumed
by the federal government, and the portion of the Medicare population eligible for
low-income assistance.  These differences are outlined in the following section.
Further details are provided in the side-by-side comparison.
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Overview of Major Proposals  
The major proposals under consideration contain a number of common themes.
They all establish a new voluntary benefit for Medicare beneficiaries under a new
Part D.  They would have a limit on the amount of federal spending for the new
benefit.  Beneficiaries would be expected to assume specified costs of the new
benefit in the form or premiums (or enrollment fees) and cost-sharing charges.  The
bills generally would pay most or all of these charges for the low-income  Other
individuals would have a limit on out-of-pocket costs (a “catastrophic limit”) once
they reached a certain level of spending.  
There are, however, a number of significant differences among the bills.  These
include the definition and scope of benefits, the degree of reliance and financial risk
placed on the private sector versus the public sector, the federal administrative
structure, and implementation of low-income subsidies.
Scope of Benefits.  A key difference among proposals is the scope of
benefits for the population not eligible for low-income assistance.  (See low-income
discussion, below.)  Under the House Democratic bill, Graham amendment, and
Graham-Smith amendment there would be one specific benefit available to all
enrollees nationwide.  Conversely, under the House-passed bill  and the “tripartisan
bill” there would be a minimum benefit level established.  Under the House-passed
bill and the “tripartisan bill”, the minimum benefit (referred to as “qualified
coverage”) would be either specified “standard coverage” or alternative coverage,
provided it was actuarially equivalent to standard coverage (i.e., had the same dollar
value) and had the same limit on out-of-pocket spending.
The scope of coverage offered under either a nationwide plan or  “standard
coverage” differs substantially by proposal.  Under both the House-passed bill and
the “tripartisan” bill, coverage would be provided for a portion of beneficiary costs
after they met a deductible; once costs reached a certain threshold, no coverage
would be provided until spending reached an out-of-pocket limit.  This coverage gap
has been labeled a “doughnut” by some. Under the House Democratic bill there
would be no coverage gap.  Under the Graham amendment, there would be no
coverage gap; however, beneficiaries would pay the full negotiated price for drugs
not on a plan’s formulary.  The Graham-Smith amendment would provide primarily
catastrophic protection for persons not eligible for low-income protection, though all
beneficiaries would have a payment made in their behalf equal to 5% of negotiated
prices for all formulary drugs up to the catastrophic limit.
All of the proposals would expect the entities administering the benefit to
negotiate prices for drugs.  These negotiated prices would be available to
beneficiaries, even if no payment was made under the new Part D.
Private vs. Public Sector Responsibility.  Virtually all proposals would
place some measure of responsibility on the private sector for administration of a
drug plan.  It is the degree of reliance placed on the public versus the private sector
that is one of the key areas of difference among the various proposals.
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3 Prior to June 14, 2001, this agency was known as the Health Care Financing
Administration (HCFA).
The House-passed bill would provide access to a drug-only benefit through
private insurance companies and other entities who wished to offer the benefit.  A
portion of the financial risk for the cost of covered benefits would be placed on the
entities administering the benefit.  In general, the private plans would be at risk for
any costs in excess of federal subsidy payments and federal reinsurance payments.
(Reinsurance payments are made to cover a portion of the costs paid by plans for
individuals incurring high costs.)  The Administrator of the new Medicare Benefits
Administration would administer the program in a manner such that eligible
individuals would be assured access to at least two plans.  If necessary to ensure
access, the Administrator would be authorized to provide financial incentives in
addition to the federal subsidy and reinsurance payments.  The “tripartisan bill”
would also rely on private entities to provide benefits and require plans to assume
some of the financial risk for the cost of covered benefits.  In order to assure access,
the Administrator of the new Medicare Competitive Agency would be authorized to
provide financial incentives for an entity to establish a plan.
Under the House Democratic bill, Graham amendment, and Graham-Smith
amendment the new benefit would be administered at the federal level like other
Medicare benefits and the federal government would bear most of the financial risk
of coverage.  The actual operation of the benefit would be through contracts with
private entities such as pharmaceutical benefit managers (PBMs).  PBMs currently
administer the drug benefit, including negotiating price discounts, for many private
insurance plans.  Under these bills, a portion of the administrative fees for these
entities would be put at risk; specifically, an adjustment would be made in
administrative payments to ensure that entities complied with requirements relating
to performance goals.
Administration.  Medicare is currently administered by the Centers for
Medicare and Medicaid Services (CMS) within the Department of Health and Human
Services (HHS).3  Two of the proposals under discussion in this report would
establish a new entity to administer the drug benefit at the federal level.  Under the
House-passed plan, a new Medicare Benefits Administration (MBA) would be
established (outside of CMS, but within HHS) to administer the drug benefit and
Medicare+Choice. Under S. 2729, the benefit would be administered by the new
Medicare Competitive Agency (also outside of CMS, but within HHS).  Under the
House Democratic bill, Graham amendment, and Graham-Smith amendment the
benefit would be administered by CMS; an advisory committee would be established
to advise the Secretary on policies related to the drug benefit.
Low-Income.  Under current law, some low-income aged and disabled
Medicare beneficiaries are also eligible for drug coverage under Medicaid.  Those
persons entitled to full Medicaid protection generally have prescription drug
coverage.  Some groups receive more limited Medicaid benefits.  Qualified Medicare
Beneficiaries (QMBs) are persons with incomes below poverty and resources below
$4,000; these persons receive Medicaid assistance for Medicare cost-sharing and
premium charges.  Specified Low Income Beneficiaries (SLIMBs) meet the QMB
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definition except that their income limit is above the QMB level; the SLIMB limit
is 120% of poverty.  QMBs and SLIMBs only receive drug benefits if they are also
entitled to full Medicaid coverage.  Under a temporary program, the SLIMB level can
be extended to certain persons under 135% of poverty who are not otherwise eligible
for Medicaid.
All of the major proposals discussed in this report would provide assistance to
persons below 150% of poverty – in terms of premiums that would have to be paid
for coverage and/or cost sharing once persons used benefits.  Both House plans
would provide for no, or very limited, beneficiary liability for covered services for
this population group.  The “tripartisan bill” would provide full premium subsidies
for those under 135% of poverty, and sliding scale subsidies for those between 135%
and 150% of poverty, provided these persons selected a plan with a premium at or
below the national weighted average, or if no such plan was available in the area,
with  the lowest premium actually available.   Under the “tripartisan bill” all persons
could be subject to some cost-sharing charges. The Graham amendment would only
provide premium assistance for persons between 135% and 150% of poverty. The
Graham-Smith amendment would provide full coverage for persons below 200% of
poverty.  No assets tests would be imposed under either the Graham amendment or
the Graham-Smith amendment.
All of the bills would pick up some of the costs now paid by the states under
Medicaid.  The proposals differ in what portion of the costs of low-income subsidies
would be paid under the current federal-state Medicaid program and what portion
would be fully paid by the federal government.
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4 For a summary of the provisions of the House-passed bill, see CRS Report RL31462,
Major Provisions of the Medicare Modernization and Prescription Drug Act of 2002, H.R.
4954, as Passed by the House, by Jennifer O’Sullivan, Hinda Ripps Chaikind, and Sibyl
Tilson.
Summary of Major Proposals
The following table is a side-by-side comparison of bills introduced in the 107th
Congress that have received the most attention to date.  These are the House-passed
bill, the House Democratic bill, the  “tripartisan bill,” the Graham amendment, and
the Graham-Smith amendment.  The summary is limited to the Medicare prescription
drug provisions.  Both House bills and the “tripartisan bill” contain additional
Medicare provisions.4 The House Democratic bill also contains drug-related
amendments to the Federal Food Drug and Cosmetic Act and the Public Health
Service Act.  The Graham amendment and the Graham-Smith amendment are limited
to Medicare prescription drug provisions.
The summary highlights the major features of the bills.  The first items provide
a broad overview (title and summary).  This is followed by an overview of program
design (beginning date, benefits, premiums, eligibility, and relationship to
Medicare+Choice).  The next section reviews administration and financial risk
(federal administration, administration of benefit, establishment of plan/benefit, plan
enrollment, federal payments to plans, assumption of financial risk, and access).  The
next items relate to pricing and cost controls (drug pricing and payment, access to
negotiated prices, and cost controls/formularies).  The next item discusses beneficiary
protections.  Then the low-income subsidy provisions are reviewed.  This is followed
by a discussion of the relationship between the new program and existing programs
which supplement Medicare benefits (Medicaid, private plans, and Medigap).  The
last item discusses the drug card and the transitional low-income assistance program
in the House-passed bill.
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Side-by-Side Comparison of Major Medicare Drug Provisions of Selected Bills
In General
Provisions H. R. 4954 H.R. 5019 (Rangel et al.) S. 2729 (Grassley et al.) S.Amdt. 4309
 (Graham et al.)
S.Amdt. 4345
 (Graham-Smith et al.) 
Title Medicare Modernization
and Prescription Drug Act
of 2002
Medicare Rx Drug Benefit
and Discount Act of 2002
21st Century Medicare Act M ed ica r e  O u t p a t i e n t
Prescription Drug Act of
2002
Medicare Prescription
Drug Cost Protection Act
of 2002
Summary Effective January 1, 2005,
a new optional benefit
would be established
under a new Part D.
Benefic i a r i e s  cou ld
purchase either a “standard
coverage” or an actuarially
equivalent coverage. In
2005, the “standard plan”
would have a $250
deductible, 20%cost-
sharing for costs between
$251 and $1,000, 50%
cost-sharing for costs
between $1,000 and
$2,000, then no coverage
until the beneficiary had
out-of-pocket costs of





provided for persons with
incomes below 175% of
poverty.   
Coverage would be
p r o v i d e d  t h r o u g h
Effective January 1, 2005,
a new optional benefit
would be established
under a new Part D. A
single benefit would be
available nationwide. In
2005, there would be a
$100 deductible, 20%
coinsurance and a limit on
out-of-pocket spending of
$2,000 ($9,600 in total
spending). Assistance
would be provided for
low-income persons with
incomes below 175% of
poverty. 
The program would be
administered by the
Secretary of Health and
Human Services (HHS);
the Secretary would enter
into  contracts  with
pharmacy contractors who
would administer the
program on a regional or
national basis. Coverage
would be provided through
M+C plans for M+C
Effective January 1, 2005,
a  new optional benefit
would be established under




coverage.  In 2005,
“standard coverage” would
have a $250 deductible,
50% cost-sharing for costs
between $251 and $3,450,
then no coverage until the
beneficiary had out-of-
pocket costs of $3,700
($5,300 in total spending);
and 10% cost-sharing
thereafter. 
The bill would rely on
private plans to provide
coverage and to bear some
of the financial risk for
drug costs.  Coverage
would be provided through
Medicare Prescription
D r u g  P l a n s  o r
Medicare+Choice (M+C)
plans.  Low income
Effective January 1, 2005,
a new optional benefit
would be established under
a new Part D. A single
benefit would be available
nationwide with no
deductible. In 2005,
enrollees would pay $10
for generic drugs, $40 for
preferred brand name
drugs, and the negotiated
price for non-formulary
drugs.  There would be a
$4,000 limit on out-of-
pocket costs. Persons with
incomes below 150% of
poverty would receive
assistance.
The program would be
administered by the
Secretary of Health and
Human Services (HHS);
the Secretary would enter





Effective January 1, 2005,
a new optional benefit
would be established under
a new Part D. A single
benefit would be available
nationwide. All enrollees
would have catastrophic
coverage and access to
negotiated prices, with the
fed e ra l  go ve rnment
assuming 5% of the
negotiated prices for drugs
on the plan’s formulary.
Once the beneficiary
incurred costs equal to the
catastrophic limit ($3,300
in 2005) they would pay
the lesser of $10 or the
negotiated price. Persons
with incomes below 200%
of poverty would have
their costs paid in full,
except for nominal
copayment amounts. 
The program would be
administered by the
Secretary of Health and
Human Services (HHS);
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Provisions H. R. 4954 H.R. 5019 (Rangel et al.) S. 2729 (Grassley et al.) S.Amdt. 4309 (Graham et al.)
S.Amdt. 4345
 (Graham-Smith et al.) 
prescription drug plans
( P D P s )  o r
Medicare+Choice (M+C)
plans. The program would
rely on private plans to
provide coverage and to
bear some of the financial
risk for drug costs; federal
subsidies would be
provided to encourage
participation.  A new
M e d i c a r e  B e n e f i t s
Administration (MBA)
would be established
within the Department of
Heal th  and  Human
Services  (HHS)  to
administer the benefit and
the M+C program.
enrollees.  The federal
government would assume
financial risk except that a
limited percentage of the
administrative payment
would be adjusted to
ensure that the contractor
pursued performance




m a n u f a c t u r e r s  t h a t
specified the maximum




provided for persons with
incomes below 150% of
poverty.
A  n e w  M e d i c a r e
Competi tive Agency
would be established
within the Department of
Heal th  and Human
Services  (HHS)  to
administer Part D and the
Medicare+Choice (M+C)
program. 
delivery systems.  The
eligible entities would
administer the benefit on a
regional basis.  Coverage
would be provided through
M+C plans for M+C
enrollees.  The federal
government would assume
financial risk, but a
p e r c e n t a g e  o f  t h e
management payments
c o u l d  b e  t i e d  t o
performance requirements
of the contracted entity.  
the Secretary would enter





delivery systems.  The
eligible entities would
administer the benefit on a
regional basis.  Coverage
would be provided through
M+C plans for M+C
enrollees.  The federal
government would assume
financial risk, but a
p e r c e n t a g e  o f  t h e
management payments
c o u l d  b e  t i e d  t o
performance requirements
of the contracted entity.  
Program Design
Provisions H. R. 4954 H.R. 5019 (Rangel et al.) S. 2729 (Grassley et al.) S.Amdt. 4309 (Graham et al.)
S.Amdt. 4345
(Graham-Smith et al.) 
Beginning Date; ending
Date
The program would begin
January 1, 2005.
The program would begin
January 1, 2005.
The program would begin
January 1, 2005.
The program would be
operational from January
1, 2005-December 31,
2010. The program would
continue after that date, if
legislation was enacted
prior to January 1, 2011,
which stated that savings
were achieved equal to or
greater than the difference
between the full cost of
The program would begin
January 1, 2005.
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Provisions H. R. 4954 H.R. 5019 (Rangel et al.) S. 2729 (Grassley et al.) S.Amdt. 4309 (Graham et al.)
S.Amdt. 4345
(Graham-Smith et al.) 
this Act over the October
1, 2004-September 30,
2012, period and the full
cost of this Act over this
period with the December
31, 2010 termination date.
Benefits “Qualified coverage”
would be either “standard
coverage” or “actuarially
equivalent coverage.”  In
2005,  “standard coverage”
would be defined as
having a $250 deductible,
20% cost-sharing for drug
costs between $251 and
$1,000, 50% cost-sharing
for drug costs between
$1,001 and the initial
coverage limit of $2,000,
and then no coverage until
the beneficiary had out-of-
pocket costs of $3,700





provided.  The dollar
amo unts  wo uld  b e
increased in future years
by the percentage increase
in the average per capita
expenditures for covered
drugs for the year ending
the previous July.  Out-of-
pocket costs counting
toward the limit would
include costs paid by the
There would be a single
nationwide benefit.  In
2005, there would be a
$100 deductible, 20%
coinsurance and a limit on
out-of-pocket spending
(including cost-sharing for
drugs covered under Part
B) of $2,000 ($9,600 in
total  spending) .  In
addition, once an enrollee
met the stop-loss limit,
they would not have to pay
any cost-sharing for drugs
covered under Part B.
These dollar amounts
would be increased in
future years by the
percentage  increase
(projected in advance by
the Secretary, for the year





preferred medicines.  For
prefer red medicines
coinsurance would equal
20% or a lower percentage
established to encourage
appropr ia te  use  o f
“Qualified coverage”




would be defined as
having a $250 deductible,
50% cost-sharing for drug
costs between $251 and
the initial coverage limit
of $3,450, then no
coverage unti l  the
beneficiary had out-of-
pocket costs of $3,700
($5,300 in total spending);
and 10% cost-sharing
thereafter. These amounts
would be increased in
future years by the
percentage increase in
average per  capita
expenditures for covered
drugs for the year ending
the previous July.  Out-of-
pocket costs counting
toward the limit would
include costs paid by the
individual (or by another
individual such as a
family member), paid on
behalf of a low-income
individual under the
There would be a single
nationwide benefit with no
deductible.  Each drug
would fall into one of three
classes:  generic, preferred
brand name, and non-
formulary.  In 2005,
enrollees would pay $10
for each  prescription filled
with a generic drug and
$40 for each prescription
filled with a preferred
b r a n d  n a m e  d r u g .
Beneficiaries would pay
the negotiated price for
non-formulary drugs,
except that  non-formulary
drugs deemed medically
necessary would be treated
as preferred brand-name
drugs.  An enrollee would
n o t  p a y  f o r  a n y
prescriptions once the
enrollee incurred out-of-
pocket costs for the year of
$4,000 (regardless of who
paid the costs).  For each
year after 2005, the
copayments would be
increased by the annual
i n c r e a s e  i n  p r i c e s
(reflecting both price





equal to: 1) 95% of the
negotiated price for
formulary drugs;  and 2)
the negotiated price for
non-formulary drugs.
Non-formulary drugs
d e e m e d  m e d i c a l l y
necessary would be treated




in 2005)  they would pay
the lesser of $10 or the
negotiated price for each
prescription whether or not
it was on the formulary.
Costs counting toward the
catastrophic limit would
include only coinsurance
charges paid by the
individual (or by another
individual such as a family
member on behalf of the
individual), Medicaid, or a
state pharmacy assistance
program. Any costs for
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Provisions H. R. 4954 H.R. 5019 (Rangel et al.) S. 2729 (Grassley et al.) S.Amdt. 4309 (Graham et al.)
S.Amdt. 4345
(Graham-Smith et al.) 
individual (or by another
individual such as a family
member), paid on behalf
of a low-income individual
und e r  th e  s u b s i d y
provisions, or paid under
Medicaid.  Any costs for
which the individual was
reimbursed by insurance
or by another third-party
payment arrangement
could not be counted.
Plans could offer more
generous drug coverage, if
approved by the MBA
Administrator.
preferred medicines.  For
nonpreferred medicines
the coinsurance would be
20% of the price for the
lowest cost preferred
medicine within the same
therapeutic class plus an
amount equal to the
amount by which the price
of the nonpreferred drug
exceeded the lowest price
preferred drug.  The extra
payments for nonpreferred
drugs would not be
considered countable cost-
sharing for purposes of
meeting the deductible or
stop-loss limit.
subsidy provisions, or
paid under Medicaid. Any
costs for which the
individual was reimbursed
by insurance or otherwise
could not be counted.
Entities could offer more
generous drug coverage, if
a p p r o v e d  b y  t h e
Administrator, but only if
they also offered a plan
p r o v i d ing  r eq u i r e d
coverage.
inflation and changes in
therapeutic mix) as
d e t e rmined  b y  t h e
Secretary for the year
ending the previous July;
this amount would be
further adjusted to reflect
relative changes in the
composition of drug
spending among generic
and preferred brand name
drugs to ensure that the
percentage beneficiaries
were required to pay was
the same as the percentage
required the preceding
year.  For each year after
2005, the out-of-pocket
limit would be increased
by the percentage increase
in average per capita
program expenditures for
the year ending the
previous July.  An eligible
entity could charge lower
copayments if such
reduction was tied to
performance requirements
and would not increase
overall program costs.  For
formulary drugs (generic
and preferred brand name
drugs), the enrollee would
pay the negotiated price
minus $5 if such amount
was less than the respective
copayment.
which the individual was
reimbursed by insurance or
otherwise could not be
counted. For each year
after 2005, the out-of-
pocket limit and the
copayment amount would
be increased by the
percentage increase in
average per capita program
expenditures for the year
ending the previous July.
An entity could reduce the
coinsurance or copayment
required if such reduction
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Premiums The plan sponsor would
establish the premium
amount,  sub jec t  to
a p p r o v a l  b y  t h e
Administrator.  The
premium for a prescription
drug plan could not vary
a m o n g  i n d i v i d u a l s
enrolled in the plan in the
same service area, unless
the individuals were
subject to penalties for late
enrollment.  Premiums
would be paid to the plans.
However, PDP sponsors
would be required to
permit each enrollee  to
pay premiums through
withholding from social
security checks in the
same manner Part B
premium payments are
withheld or through an
electronic funds transfer.
Premiums would be set at
$25 per month for 2005.
This amount would be
increased in future years
by the percentage increase,
(projected in advance by
the Secretary, for the year
involved) in per capita
program expenditures.
Enrollees would pay
p r e m i u m s  t h r o u g h
withholding from social
security checks in the
same manner Part B
premium payments are
withheld.  Late enrollment
penalties, calculated in the
same manner as such
penalties are calculated for
Part B, would be applied
to persons who did not
enroll during their initial
enrollment period or
d u r i n g  a  s p e c i a l
e n r o l l m e n t  p e r i o d
es tab l i shed  due  to
involuntary loss of other
drug coverage.
Monthly premiums would
be uniform for all eligible
beneficiaries in a plan,
except that persons
d e l a y i n g  P a r t  D
enrollment without other
creditable drug coverage
would be subject to higher
premiums.  If the plan’s
m o n t h l y  a p p r o v e d
premium for standard
coverage  was equal to the
national monthly weighted
average premium for such
coverage, the beneficiary
would pay: 1) 57% of the
monthly national average.
If the plan’s monthly
approved premium was
less than the national
average the beneficiary
would pay: 1) 57% of the
monthly national average,
minus, 2) the difference
between the national
average and the plan’s
premium. If the plan’s
monthly premium  was
greater than the national
average, the beneficiary
would pay: 1) 57% of the
monthly national average,
plus 2) the difference
between the national
average  and the plan’s
premium. Premiums
Premiums would be set at
$25 per month for 2005.
This amount would be
increased in future years by
the percentage increase,
(projected in advance by
the Secretary, for the year
involved) in average per




social security checks in
the same manner Part B
premium payments are
withheld.  Late enrollment
penalties would be applied
to premiums for persons
who did not enroll during
their initial enrollment
period or during a special
e n r o l l m e n t  p e r i o d
es t ab l i shed  d ue  to
involuntary loss of other
drug coverage.
There would be no
premiums. There would be
an annual enrollment fee.
In 2005 it would be $25;
this amount would be
increased in future years by
the percentage increase in
average per capita program
payments for the year
ending the previous July.
Unless they elected direct
payment,  enrollees would
pay enrollment fees
through withholding from
social security checks in
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would be collected in the
same manner as Part B
premiums.
Eligibility All beneficiaries enrolled
in Medicare Part A or Part
B could elect to enroll in
Part D through enrollment
in a M+C plan with
prescription drug coverage
or in a PDP.  The
Administrator of the new
MBA would establish an
enrollment process. An
initial election period
would be established.  For
current beneficiaries this
would be the 6-month
p e r i o d  b e g i n n i n g
November 2004; for future
beneficiaries it would be
the same 7-month period
applicable for initial Part B
enrollment.  Special
election periods would
apply for persons who
involuntarily lose other
drug coverage.  Persons






otherwise they could be
subject to late enrollment
penalties.
All beneficiaries enrolled
in Medicare Part A or
eligible to enroll in Part B
could elect to enroll in Part
D.  An initial enrollment
p e r i o d  w o u l d  b e
established.  For current
beneficiaries this would be
the 7-month period
beginning August 1, 2004;
for future beneficiaries it
would be the same 7-
month period applicable
for  in i t ia l  Par t  B
enrollment.  Special
enrollment periods  would





persons would not be
subject to late enrollment
penalties.
All beneficiaries enrolled
in Medicare Parts A and B
could elect to enroll in
Part D.  The Administrator
would establish an
enrollment process which
would be similar to that
for Part B. An initial open
enrollment period would
be established. For current
beneficiaries, this would
be the 8-month period
beginning April 1, 2004.
Eligible beneficiaries with
creditable drug coverage
could elect to continue to
receive such coverage, not
enroll in Part D, and
subsequently enroll in Part




apply for this group.
All individuals enrolled in
Part A or Part B could elect
to enroll in Part D.  The
Secretary would establish
an enrollment process.  An
initial enrollment period
would be established.  For
current beneficiaries, this
would be a period of time
d e t e r mined  b y the
Secretary before January 1,
2005, so that Part D
coverage was effective as
of such date.  For future
b e n e f i c i a r i e s ,  t h e
enrollment procedures
would be similar to those
used for Part B.  Eligible
b e n e f i c i a r i e s  w i t h
creditable drug coverage
could elect to continue to
receive such coverage, not
enroll in Part D, and
subsequently enroll in Part




apply for this group.
All individuals enrolled in
Part A or Part B could elect
to enroll in Part D. The
Secretary would establish a
process through which an
eligible beneficiary could
elect to enroll at any time,
terminate enrollment at any
time and reenroll at any
time. The Secretary would
e s t a b l i s h  a n  o p e n
enrollment period of at
least 5 months so indivuals
who are or will be eligible
by January 1, 2005, would
be permitted to enroll prior
to that date and have
coverage begin on that
date. 
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R e l a t i o n s h i p  t o
Medicare+Choice
An M+C enrollee would
obtain benefits through the
M+C plan if the plan
provided qualified drug
coverage.  An M+C plan
could not offer drug
coverage (other than that
already required under
Medicare) unless the




be required offer plans
with drug coverage that
was at least actuarially
equivalent to Part D
benefits.  An M+C
enrollee would be required
to obtain Part D drug
benefits through the plan.
An M+C enrollee would
obtain benefits through
the M+C plan if the plan
provided qualified drug
coverage. An M+C plan
offering drug coverage
would have to make a
p lan offer ing only
s t a n d a r d  c o v e r a g e
available to each Part D
enrollee. An organization
could also offer additional
qualified drug coverage.
Drug coverage could not
be offered to an enrollee
unless the enrollee was
enrolled in Part D.
M+C organizations would
be required to offer Part D





be required to offer Part D
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Federal Administration The new MBA, within
HHS, would administer the
new Part D drug benefit
and the M+C program.
(The Centers for Medicare
and Medicaid Services
(CMS),  would retain
responsibility for the
traditional fee-for-service




The Secretary  (through
CMS) would administer
the benefit.  A newly
c r e a t e d  M e d i c a r e
Prescription Medicine
Advisory Committee
w o u l d  a d v i s e  t h e
Secretary.
The Administrator of the
new Medicare Competitive
Agency, within HHS,
would administer Part D
and the M+C program.




C o mp e t i t i ve  P o l i cy





the benefit.  A newly
c r e a t e d  M e d i c a r e
P r e s c r i p t i o n  D r u g
Advisory Committee
w o u l d  a d v i s e  t h e











the benefit. A newly
c r e a t e d  M e d i c a r e
P r e s c r i p t i o n  D r u g
Advisory Committee
w o u l d  a d v i s e  t h e









Administration of benefit The benefit would be
administered by a M+C
plan or PDP.  A PDP plan
sponsor would be an entity
certified under Part D as
meeting the Part D
s t a n d a r d s  a n d
requirements.  In general,
a PDP sponsor would have
to be licensed under state
law as a risk bearing entity
eligible to offer health
b e n e f i t s  o r  he a l th
insurance coverage in each
state in which it offered a
prescription drug plan.  
The benefit would be
administered by pharmacy
contractors serving on a
regional or national basis.
The benefit could be
administered on a partial
r e g i o n a l  b a s i s ,  i f
determined appropriate by
the Secretary.  The
Secretary would determine
regions and assure that
there were at least 10 in
the U.S.  Coverage would
be provided through M+C
plans for M+C enrollees.
Contractors would be
required to meet Part D
requirements.  They would
The benefit would be
administered by an M+C
plan or a Medicare
Prescription Drug Plan
offered by an entity in the
geographic area. Entities
eligible to  offer plans







pharmacis t  de l ivery
system; an insurer, another
entity, or any combination
of entities. In general,
The benefit would be
administered by M+C
plans or by eligible entities
serving on a regional basis.
The benefit could be
administered on a partial
r e g i o n a l  b a s i s ,  i f
determined appropriate by
the Secretary; however the
area could never be
smaller than a state. An
entity could submit a
single bid to provide
coverage in multiple
regions.  The Secretary
would determine regions
and assure that there were
at least 10 in the U.S.
The benefit would be
administered by M+C
plans or by eligible entities
serving on a regional basis.
The benefit could be
administered on a partial
r e g i o n a l  b a s i s ,  i f
determined appropriate by
the Secretary; however the
area could never be
smaller than a state. An
entity could submit a
single bid to provide
coverage in multiple
regions.  The Secretary
would establish regions
and assure that there were
at least 10 in the U.S.
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entities would have to be
licensed under state law as
risk bearing entities.
The Administrator would
be required to establish by
April 15, 2004, and
periodical ly review,
service areas in which
plans could offer benefits.
The area covered by a plan
would be either 1 entire
service area established by
the Administrator or the
entire country.  Plans
could submit multiple bids
for multiple service areas.
Entities would be required
t o  m e e t  P a r t  D
requirements.  They would





Entities would be required
t o  m e e t  P a r t  D
requirements.  They would
be authorized to negotiate
and enter into participation
a g r e e m e n t s  w i t h
pharmacies that comply
w i t h  p r o g r a m
requirements. 
Submission of bids Each PDP sponsor would
be required to submit to
the MBA Administrator
information on the
qualified drug coverage to
be provided including the




reflected:  1) the value of
benefits provided; and 2)
the 67% federal subsidy
for standard benefits.  PDP
plan sponsors would be
required to enter into a
c o n t r a c t  w i t h  t h e
Administrator; the contract
The Secretary would enter





from entities.  The bid
would include:  a proposal
for the estimated drug
prices and projected
annual increases in prices,
a statement regarding what
it would charge the
Secretary to administer the





enter into contracts with
eligible entities; contracts
could cover more than one
plan.  Entities would
submit bids containing
information on the plan
including the monthly





value of the benefits and
reinsurance subsidies. The
Administrator would have
the same authority to
negotiate the terms and
The Secretary would enter
into contracts with eligible





systems, health plans or
insurers, states, or any
other entity or combination
of entities.  The Secretary
would accept competitive
bids from entities.  The bid
would include: a proposal
for estimated drug prices
and projected annual
increases in prices, a
statement regarding what it
The Secretary would enter
into contracts with eligible





systems, health plans or
insurers, states, or any
other entity or combination
of entities.  The Secretary
would accept competitive
bids from entities.  The bid
would include: a proposal
for estimated negotiated
drug prices and projected
annual increases in prices,
a statement regarding what
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could cover more than one
plan.  The Administrator
would have the same
authority to negotiate the
terms and conditions of the
plans as the Director of the
Office of  Personnel
Management has with




deta i led  descr ipt ion
standards the entity would
use in selecting preferred
med ica t i o ns .   T he
Secretary would award, on
a competitive basis
contracts for 2-5 year
terms.  At least two
contracts would be
awarded per area unless
only one entity submitted a
bid meeting minimum
standards.  The Secretary
would consider the
comparative merits of each
bid.  
conditions of the plans as
the Director of the Office
of  Personnel Management
has with respect to Federal
Employee Health Benefits
(FEHB) plans.  The
Administrator would
approve at least two
contracts to offer a
Medicare prescription plan
in an area. Contracts
would be awarded for 1-
year.
would charge the Secretary
to administer the benefit, a





the entity would use in
modifying the formulary.
The Secretary would
award, on a competitive
basis  contracts for 2-5
year terms.  At least two
contracts would be
awarded per area unless
only one entity submitted a
bid meeting minimum
standards.  The Secretary
would consider the
comparative merits of each
bid.
it would charge the
Secretary to administer the
benefit, a description of
access to pharmacy
services, a description of
performance requirements,
and a description of
standards the entity would
use in modifying the
formulary. The Secretary
would award, on a
c o m p e t i t i v e  b a s i s
contracts for 2-5 year
terms.  At least two
contracts would be
awarded per area unless
only one entity submitted a
bid meeting minimum
standards.  The Secretary
would consider the
comparative merits of each
bid.
Plan enrollment Beneficiaries would enroll
a  M+C plan wi th
prescription drug coverage
or in a PDP.  
Each individual would
select (and could change
the selection on a periodic
basis) the pharmacy
contractor to administer
the benefit for such
individual.
Eligible beneficiaries not
e n r o l l e d  i n  a
Medicare+Choice plan
would make an election to
enroll in a Medicare
Prescription Drug Plan and
could make an annual
election to change plans. A
Part D enrollee  who failed
to enroll in a plan would
be enrolled in the plan
with the lowest monthly
premium available in the
area.
Eligible beneficiaries not
enrolled in a M+C plan
would make an annual
election to enroll in a
Medicare Prescription
Drug Plan.  A default
option would be selected
by the Secretary for
enrollees that failed to
select an entity.
Eligible beneficiaries not
enrolled in a M+C plan
would make an annual
election to enroll in a
Medicare Prescription
Drug Plan.  A default
option would be selected
by the Secretary for
enrollees that failed to
select an entity.
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Federal payments to plans The federal government
would pay direct subsidies
and reinsurance payments
to PDPs,  M+C plans, and
qualified retiree plans
which would equal 67% of
the value of standard
coverage.  Direct subsidies
would be equal to 37% of
the value of standard
coverage provided under
the plan.  Reinsurance
payments would be equal
to 30% of the value of
s t a n d a r d  c o v e r a g e .
Reinsurance payments
would be provided for: 1)
30% of an individual’s
allowable drug costs
between $1,001 and
$2,000 (in 2005); and 2)
80% for costs over the out-
of-pocket limit ($3,700 in
2005).  The Administrator
would proportionately
adjust payments so that
total reinsurance payments
for the year equaled 30%
of total payments by
qualifying plans for
standard coverage during
t h e  y e a r .   T h e
Administrator could adjust
direct subsidy payments in
order to avoid risk
selection. 
The Secretary would pay
each pharmacy contractor
for the administration of




for prescription drugs used
by enrollees.  The
Secretary would include in
the contract with a
pharmacy contractor
incentives for cost and
utilization management
and quality improvement;
the contract could provide
financial incentives to
encourage greater program
savings.  The Secretary




if the standards were met
and penalties if they were




entities, M+C plans, and
qualified retiree plans
which would equal 30% of
the value of standard
coverage.  Reinsurance
payments would be
provided for: 1) 50% of an
individual’s allowable
drug costs between $2,001
and $3,450 (in 2005); and
2) 80% for costs over the
out-of-pocket limit ($3,700
i n  2 0 0 5 ) .   T h e
Administrator would
proportionately adjust
payments so that total
reinsurance payments for
the year equaled 30% of
t o t a l  p ayment s  b y
qualifying plans for
standard coverage during
the year.  
The Secretary would pay
each eligible entity for the
management of the benefit
and for the negotiated
price (less cost sharing) of
prescription drugs used by
enrollees.  A percentage of
the management payment
(as determined by the




care, and providing quality
service.  The Secretary
could reduce payments to
reflect rebates and price
concessions obtained by
t h e  e n t i t y  f r o m




would provide for payment
of a reasonable dispensing
fee.
The Secretary would pay
each eligible entity for the
management of the benefit
and for the negotiated
price (less cost sharing) of
prescription drugs used by
enrollees.  A percentage of
the management payment
(as determined by the




care, and providing quality
service.  The Secretary
could reduce payments to
reflect rebates and price
concessions obtained by
t h e  e n t i t y  f r o m




would provide for payment
of a reasonable dispensing
fee.
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Assumption of financial
risk
Plans would be required to
assume full financial risk
on a prospective basis for
covered benefits except:
1) as covered by federal
direct subsidy payments or
reinsurance payments for
high cost enrollees; or 2)
as covered by federal
incentive payments to
encourage plans to expand
service areas for existing
plans or establish new
plans.  The entity could
obtain insurance or make
other arrangements for the




risk for the cost of benefits
except that a limited
p e r c e n t a g e  ( t o  b e
d e te rmined  b y the
S e c r e t a r y )  o f  t h e
administrative payment
would be adjusted to
ensure that the contractor
pursues performance
r e q u i r e m e n t s ;  t h e
Secretary could not
establish a percentage that
would jeopardize the
ability of the contractor to
administer the benefits in a
quality manner.
Entities would be required
to assume a portion of
financial risk. Entities
would be permitted to
obtain reinsurance for the
portion of costs for which
they were at risk.
The federal government
would assume financial
risk for the cost of benefits
except that a percentage
(to be determined by the
S e c r e t a r y )  o f  t h e
administrative payment
would be adjusted to
ensure that the contractor
pursued performance
requirements.   The
percentage could be up to
100%.  The Secretary
could not establish a
percentage that would
jeopardize the ability of
t h e  c o n t r a c t o r  t o




risk for the cost of benefits
except that a percentage
(to be determined by the
S e c r e t a r y )  o f  t h e
administrative payment
would be adjusted to
ensure that the contractor
pursued performance
requirements.   The
percentage could be up to
100%.  The Secretary
could not establish a
percentage that would
jeopardize the ability of
t h e  c o n t r a c t o r  t o
administer the benefits in a
quality manner.
Access The Administrator would
assure that all eligible
individuals residing in the
U.S. would have a choice
of enrollment in at least
two qualifying plan
options (at least one of
which was a PDP) in their
area of residence.  The
requirement would not be
satisfied if only one PDP
s p o n s o r  o r  M + C
organization offered all the
qualifying plans in the
area.  If necessary to
ensure such access, the
Administrator would be
The Secretary would
develop procedures for the
provision of Part D
benefits to persons
residing in areas not




residing in more than one
area in a year were
p r o v i d e d  b e n e f i t s
throughout the year.
In order  to assure access,
the Administrator would
be authorized to provide
financial  incentives,
including the partial
underwriting of risk, for an
entity to establish a plan;
the assistance would be
available only so long as,
and  to  the  extent
necessary, to assure the
g u a r a n t e e d  a c c e s s .
H o w e v e r ,  t h e
Administrator could never
provide for the full
underwriting of financial
risk for any entity, nor
The Secretary would
develop procedures for the
provision of Part D
benefits to persons
residing in areas not




residing in more than one
area in a year were
p r o v i d e d  b e n e f i t s
throughout the year.
The Secretary would
develop procedures for the
provision of Part D
benefits to  persons
residing in areas not




residing in more than one
area in a year were
p r o v i d e d  b e n e f i t s
throughout the year.
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underwriting of risk, for a
PDP sponsor to expand its
service area under an
existing prescription drug
plan to adjoining or
additional areas, or to
establish such a plan,
including offering such
plan on a regional or
nationwide basis.  The
assistance would be
available only so long as,
and  to  the extent
necessary, to assure the
g u a r a n t e e d  a c c e s s .
H o w e v e r ,  t h e
Administrator could never
provide for the full
underwriting of financial
risk for any PDP sponsor,
n o r  c o u l d  t h e
Administrator provide for
any assump t ion of
financial risk for a public
PDP sponsor offering a
nationwide drug plan.
A d d i t i o n a l l y ,  t h e
Administrator would be
directed to seek to
maximize the assumption
of financial risk by PDP
sponsors  and M+C
organizations.
could the Administrator
p r o v i d e  f o r  a n y
assumption of financial
risk for a public entity
offering a nationwide drug
plan.  Additionally, the
Administrator would be
directed to seek to
maximize the assumption
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Drug pricing and payment The PDP sponsor would
determine payments and
would be expected to
negotiate discounts. 




the maximum prices that
may be charged to
program enrollees.  The
Secretary would be
required to take into
account the goal of
developing breakthrough
medicines.
The entity offering the
drug plan would determine




bid would include a
proposal for the estimated
prices for covered drugs
and projected annual
increase in prices.  The
entity would be expected
to negotiate prices.
The contracting entity’s
bid would include a
proposal for the estimated
negotiated prices for
covered  d rugs  and
projected annual increase
in prices.  The entity
would be expected to
negotiate prices.
Access to negotiated prices Both standard coverage
and actuarially equivalent
coverage would have to
provide beneficiaries
access to negotiated prices
(including applicable
discounts) even when no
benefits may be payable
because the beneficiary
had reached the initial
coverage limit.
The contract between the
S e c r e t a r y  a n d  t h e
pharmacy contractor
wo ul d  r e q u i r e  the
contractor to negotiate
c o n t r a c t s  w i t h
manufacturers that provide
for maximum prices that
are lower than those
n e g o t i a t e d  b y  t h e
Secretary, if applicable.
The reduction would be
passed on to beneficiaries









coverage would have to
provide beneficiaries
access to negotiated prices
(including applicable
discounts) even when no
benefits may be payable
because the beneficiary
has reached the initial
coverage limit.
An entity offering a plan
would be required to issue
a card to the beneficiary to
assure access to negotiated
prices for which coverage
is not otherwise provided
under the plan.
Plans would provide that
beneficiaries would have
access to negotiated prices
Plans would have to
provide beneficiaries
access to negotiated prices
(including applicable
discounts) even when no
benefits may be payable
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Cost controls/formularies Plans would be allowed to
h a v e  f o r m u l a r i e s
restricting coverage to
certain drugs.  Plans
electing to use a formulary
would be required to
establish a pharmaceutical
and therapeutic committee
(that included at least one
practicing physician and
one practicing pharmacist)
to develop and revise the
formulary.  The formulary
would be required to
include drugs within all
therapeutic categories and
classes of covered drugs
(although not necessarily
for all drugs within such
categories and classes).
Plans could offer tiered
cost-sharing for drugs
i n c l u d e d  wi t h i n  a
formulary and lower cost-
sharing for preferred drugs
in the formulary.  An
enrollee would have the
right to appeal to obtain
coverage for a drug not on
the formulary if the
prescribing physician
determined that the
formulary drug was not as
effective for the individual
or had adverse effects for
the individual.  
Preferred medic ines
(which would have lower
cost sharing) would be
d e s i g n a t e d  b y  th e
Secretary or the pharmacy
contractor for a therapeutic
c l a s s .  P h a r m a c y
contractors would be
required to have in place
procedures to treat, on a
case-by-case basis, non-
preferred medicines as
preferred medicines if the
preferred medicine was
determined not to be as
effective for, or to have
significant adverse effects





condition of the enrollee
and medical evidence.





a p p r o p r i a t e l y  a n d
efficiently; mechanisms
could include:  1) price
negotiations; 2) reduction
in coinsurance below 20%
for preferred medicines; 3)
Plans would be allowed to
h a v e  f o r m u l a r i e s
restricting coverage to
certain drugs.  Plans
electing to use a formulary
would be required to
establish a pharmaceutical
and therapeutic committee
(that included at least one
practicing physician and
one practicing pharmacist)
to develop and revise the
formulary.  The formulary
would be required to
include drugs within all
therapeutic categories and
classes of covered drugs
(although not necessarily
for all drugs within such
categories and classes).
Plans could offer tiered
cost-sharing for drugs
i n c l u d e d  wi t h i n  a
formulary and lower cost-
sharing for preferred drugs
in the formulary.  An
enrollee would have the
right to appeal to obtain
coverage for a drug not on
the formulary if the
prescribing physician
determined that the
formulary drug was not as
effective for the individual
or had adverse effects for
the individual. If a plan
Entities would be required
to use cost control
strategies that could
i n c l u d e  a l t e r n a t i v e
methods of distribution
(though beneficiaries
would not be required to
use such alternative









generic and brand name
drugs.
Entities would be required
to establish formularies.
There could not be a
national formulary, nor
could the Secretary require
an entity to exclude a
particular drug from the
formulary.  The formulary




by the Secretary in
consultation with the
Medicare Prescription
D r u g  A d v i s o r y
Entities would be required
to use cost control
strategies that could
i n c l u d e  a l t e r n a t i v e
methods of distribution
(though beneficiaries
would not be required to
use such alternative









generic and brand name
drugs.
Entities would be required
to establish formularies.
There could not be a
national formulary, nor
could the Secretary require
an entity to exclude a
particular drug from the
formulary.  The formulary




by the Secretary in
consultation with the
Medicare Prescription
D r u g  A d v i s o r y
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methods  to  reduce
medication errors and
encourage appropriate use
of medications; and 4)
permitting pharmacy
contractors, as approved
by the Secretary, to make
exceptions to the cost-
sharing provisions for
nonpreferred medicines, to
secure best prices for
enrollees.
Price negotiations would
be conducted in such  a
manner so that:  1) there
was at least one contract
for a medicine in each
therapeutic class; 2) if
more than one medicine
was available in a class,
there were contracts for at
least two medicines in the
class unless determined
clinically inappropriate;
and 3) if more than two
medicines were available
in a class, there were
contracts for at least two
medicines in a class and a
contract for a generic




for covered drugs, an
enrollee would have the
right to request that a
nonpreferred drug be
treated on terms applicable
for a preferred drug if the
prescribing physician
determined that the
preferred drug was not as
effective for the individual
or had adverse effects for
the individual.
Eligible entities would be




reduce  cos ts  when
appropriate).  Entities
could use other cost




C o m m i t t e e .   T h e
formulary would have to
include:  1) all generic
covered drugs, and 2) at
least one but no more than




w a s  c l i n i c a l l y
inappropriate for a given
therapeutic class.  
Entities would have to
have procedures to  treat
non-formulary drugs as
preferred brand-name
drugs if the preferred drug
was determined not to be
as effective for the enrollee
in preventing or slowing
the deterioration of, or
improving or maintaining
the health of the enrollee
or to have a significant
adverse effect for the
enrollee.
C o m m i t t e e .   T h e
formulary would have to
include:  1) all generic
covered drugs, and 2)
drugs for each therapeutic
category and class though
not necessarily all drugs in
each category or class. 
Entities would have to
have procedures to  treat
non-formulary drugs as
brand-name drugs on the
formulary if the formulary
drug was determined not
to be as effective for the
enrollee in preventing or
slowing the deterioration
of, or improving or
maintaining the health of






to participate in cost and
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Beneficiary protections Plans would be required to
comply with a number of
beneficiary protection
provisions including those
related to:  1) community-
rated premiums; 2) non-
d i s c r i m i n a t i o n ;  3 )
information disclosure; 4)
assuring the participation
of a sufficient number of
pharmacies; 5) issuance of
a card so beneficiaries
could assure access to
negotiated prices when
coverage is not otherwise
available under the plan;
6) a cost and drug
utilization management
p r o g r a m  i n c l u d i n g
med ica t i o n  t h e r a p y
management and an
electronic prescription
drug program that provides
for electronic transfer of
prescriptions and provision
of information to the
p r e s c r i b i n g  h e a l t h
professional; and 7)





programs for quality and
other standards including
those related to:  1) access
(including 24-hour/7-day a
week access, on-line
review to evaluate for
m e d i c i n e  t h e r a p y
problems, and adherence
of any preferred pharmacy
network to minimum
a c c e s s  s t a n d a r d s ) ;
2)assuring compliance of





and 5) provision of cost
data to the Secretary.
Pharmacy contractors
would be required to have
in place procedures to
ensure timely procedures
for internal and external
review of denials of
coverage and other
complaints.
Eligible entities would be
required to:  1) disclose
i n f o r m a t i o n  t o
beneficiaries on the plan;
2) secure the participation
in the network of a
sufficient number of
pharmacies that dispense
drugs directly to patients
(other than by mail order)
to ensure convenient
access for beneficiaries; 3)
have quality assurance
measures, including a
med ica t i o n  t h e r ap y
management program, to
reduce medical errors and
adverse drug interactions;
4) assure that beneficiaries
were informed at the time
of purchase of any
difference between the
price of  the prescribed
drug and the lower priced
generic drug; 5) provide
procedures for resolving
grievances and handling
appeals; and 6) assure
confidentiality of enrollee
records.  Entities could
establish an optional point-
of-service method of
operation under which the
plan provided access to
The Secretary could not
award a contract to an
entity unless the entity:  1)
met quality and financial




drugs and avoidance of
adverse drug reactions; 3)





a n d  p r o v i s i o n  o f
informa t ion to  the
p r e s c r i b i n g  h e a l t h
professional; 4) ensured 24
hour/7-day a week access
to drugs in emergencies; 5)
ensured that pharmacies
would not overcharge




7) had an appeals process
for enrollees; 8) had
procedures to safeguard
the privacy of medical
records; and 9) had
procedures to deter
medical errors and ensure
The Secretary could not
award a contract to an
entity unless the entity:  1)
met quality and financial




drugs and avoidance of
adverse drug reactions; 3)





a n d  p r o v i s i o n  o f
in format ion to  the
p r e s c r i b i n g  h e a l t h
professional; 4) ensured 24
hour/7-day a week access
to drugs in emergencies; 5)
ensured that pharmacies
would not overcharge




7) had an appeals process
for enrollees; 8) had
procedures to safeguard
the privacy of medical
records; and 9) had
procedures to deter
medical errors and ensure
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any or all pharmacies not
participating in the
network and could charge
beneficiaries, through
a d j u s t m e n t s  i n
copayments, additional






Low-Income Subsidies for Part D
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Subsidies for Part D Lo w- i n c o me  p e r s o n s
would receive a premium
subsidy (based on the
v a l u e  o f  s t a n d a r d
coverage).  Individuals
with incomes at or below
150% of poverty (and
assets below $4,000)
would have a subsidy
equal to 100% of the value
of standard drug coverage
provided under the plan.
Individuals with incomes
between 150% and 175%
of poverty would have a
sliding scale premium
subsidy ranging from
100% of such value at
150% of poverty to 0% of
such value at 175% of
poverty.  For both groups,
beneficiary cost-sharing





incomes below 100% of
poverty and assets below
$4,000), and persons
me e t i n g  t h e  Q M B
definition except that their
incomes were between
100% and 150% of
poverty, would have their
P a r t  D  p r e mi u ms ,
deductibles, and countable
cost sharing paid by
Medicaid.  Persons
me e t i n g  t h e  Q M B
definition except that their
incomes were between
150% and 175% of
poverty would have their
Part D deductibles and
countable cost-sharing
Persons with incomes
below 135% of poverty
and assets below $4,000
would have a full premium
subsidy, provided the plan
premium was at or below
the national weighted
average premium. If no
such plan was available in
the area, the subsidy would
equal the premium for the
lowest cost plan. In
addition, these persons
would  have :  1 )  a
deductible equal to 5% of
the amount otherwise
applicable; 2) cost-sharing
of 2.5% rather than 50%
for costs below the initial
coverage limit; 3) 50%
cost-sharing for costs
above the initial coverage




(QMBs, i.e., persons with
incomes below 100% of
poverty), and persons
me e t i n g  t h e  Q M B
definition except that their
incomes were between
100% and 135% of
poverty, would have their
Part D premiums and
copayments paid by
Medicaid.  Enrollees
between 135% and 150%
of poverty would pay a
reduced Part D premium,
calculated on a sliding
scale basis.  In determining
QMB qualification for
payment of Part D
p r e m i u m s  a n d
c o p a y m e n t s ,  a s s e t
Persons whose income , as
defined under the QMB
program, was below 200%
of poverty would have
their Part D cost-sharing
and enrollment fees paid
by Medicaid. No assets
requirements would be
imposed.  Beneficiaries
would be subject to cost-
sharing charges of $2 for
generic drugs and $5 for
brand name drugs. The
cost-sharing charges for
years after 2005 would be
i n c r e a s e d  b y  t h e
percentage increase in
average per capita program
expenditures for the year
ending the previous July.
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initial coverage limit
($2,000 in 2005) would be
reduced to an amount not
to exceed $2 for a multiple
source or generic drug and
$5 for a non-preferred
drug. No deductible would
be imposed.  PDPs could
not charge individuals
receiving cost-sharing
subsidies more than $5 per
prescription. PDPs could
reduce to zero the cost-
s h a r i n g  o t h e r w i s e
applicable for generic
drugs.
paid by Medicaid; their
Part D premiums would be
reduced on a sliding scale
basis ranging from 100%
of the premium at 150% of
poverty to 0% at 175% of
poverty.
out-of-pocket limit; and 4)
zero cost sharing for costs
above the out-of-pocket
limit.  Persons with
incomes above 135% and
below 150% of poverty
would have a sliding scale
premium ranging from
100% of the premium at
135% of poverty to 57% of
poverty with no additional
premium costs provided
the plan premium was at or
below the na t iona l
weighted average premium
(or the lowest premium in
the area if none was below
the national weighted
average).  They would also
have 50% cost-sharing for
costs between the initial
coverage limit and the
annual out-of-pocket limit.
Plans could waive or





Relationship to Other Coverage
Provisions H. R. 4954 H.R. 5019 (Rangel et al.) S. 2729 (Grassley et al.) S.Amdt. 4309
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Relationship to Medicaid States would be required to
m a k e  e l i g i b i l i t y
determinations for low-
income subsidies; there
would be a phase-in of the
federal assumption of
associated administrative
costs.  (Alternatively, the
eligibility determinations
could be made by the
S o c i a l  S e c u r i t y
Administration.)  There
would also be a federal
phase-in of the costs of
premiums and cost-sharing
subsidies for dual eligibles.
States would be required to
maintain Medicaid benefits
as a wrap around to
Medicare benefits for dual
eligibles; states could
require that these persons
elect Part D drug coverage.
If a state elected to use
negotiated prices for a
drug under its Medicaid
program, the Medicaid
rebate requirements would
not apply for that drug.
Further, the bill would
exempt  any p r i ce s
negotiated by a PDP,
Medicare+Choice plan, or
Medicaid costs associated
with paying Part D cost-
sharing charges for
persons with incomes
above 100% of poverty
would be paid by the
federal government.
States would be required to
m a k e  e l i g i b i l i t y
determinations for low-
income subsidies; there
would be a phase-in of
federal assumption of
associated administrative
costs. There would also be
a federal phase-in of a
portion of the costs of
premiums and cost-sharing
subsidies for dual eligibles.
Medicaid coverage would
wrap around Part D
benefits; states could
require that these persons
elect Part D drug coverage.
If a state elected to use
negotiated prices for a
drug under its Medicaid
program, the Medicaid
rebate requirements would
not apply for that drug.
Further, the bill would
exempt  any pr ice s




f r o m  M e d i c a i d ’ s
determination of “best
price” for purposes of the 
The current federal-state
matching rate would apply
for  Medicaid costs
associated with paying
Part D premiums and cost-
sharing for those below
120% of poverty.  The
federal matching rate
would be 100% for those
between 120% and 150%
of poverty. 
If a state elected to use
negotiated prices for a
drug under its Medicaid
program, the Medicaid
rebate requirements would
not apply for that drug.
Further, the bill would
exempt  any p r ices




f r o m  M e d i c a i d ’ s
determination of “best
price” for purposes of the
Medicaid rebate program.
The current federal-state
matching rate would apply
for  Medicaid costs
associated with paying
Part D cost-sharing and
enrollment fees for those
below 120% of poverty.
An enhanced matching
rate would apply for
persons with incomes
between 120% and 150%
of poverty. This rate would
be defined as the federal
matching rate for the
state’s Medicaid program
plus 30% of the percentage
point difference between
this rate and 100%; in no
case could the rate exceed
8 5 % .  T h e  f e d e r a l
government would pay
100% of costs for persons
between 150% and 200%
of poverty.  States would
be required to make the
eligibility  determinations.
If a state elected to use
negotiated prices for a
drug under its Medicaid
program, the Medicaid
rebate requirements would
not apply for that drug.
Further, the bill would
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f r o m  M e d i c a i d ’ s
determination of “best





exempt  any p r i ce s




f r o m  M e d i c a i d ’ s
determination of “best





plans offered by employers
to retirees would be
eligible for direct subsidies
and reinsurance payments.
At a minimum, qualified
retiree coverage would
have  to  mee t  the
requirements for qualified
p r e s c r i p t i o n  d r u g
coverage.
The Secretary would make
payments to retiree health
plans offering coverage
that was not less than Part
D coverage. Payments
would equal two-thirds of
the estimated average per
c a p i t a  g o v e r n m e n t
contribution for Part D
enrollees.
Qualified prescription drug
plans offered by employers
to retirees would be
eligible for reinsurance
payments.  At a minimum,
qualified retiree coverage
would have to meet the
requirements for qualified
p r e s c r i p t i o n  d r u g
coverage.
The Secretary would make
payments to retiree health
plans offering coverage
that was not less than Part
D coverage.  Payments
would equal two-thirds of
the estimated average per
c a p i t a  g o v e r n m e n t
contribution for Part D
enrollees.
The Secretary would make
payments to retiree health
plans offering coverage
that was not less than Part
D coverage.  Payments
would equal three-fourths
of the estimated average
per capita government
contribution for Part D
enrollees.
Relationship to Medigap Effective January 1, 2005,
the issuance of new
Medigap policies with
prescription drug coverage
would be prohibited unless
1) the policies replaced
another policy with drug
coverage; or 2) policies
met requirements for two
new standardized policies
for all Medicare services.
The first new policy would
have the following benefits
(notwithstanding other
provisions of law relating
The bill would modify
current requirements for
standardized Medigap
policies.  Effective January
1, 2005, an appropriate
number of such polices
would have to provide
coverage for medicines
which complemented, but
did not duplicate, Part D
benefits.
Effective January 1, 2005,
no Medigap policy with
drug coverage could be
sold, issued, or renewed to




designed to supplement the
new enhanced fee-for-
service coverage option
under the bill; these
policies could not offer
coverage for drug costs.
The three of the 10
standardized Medigap
plans offering drug
coverage would have to be
revised to complement, not
duplicate, Part D.  The
revised drug packages
could not offer coverage
for more than 90% of the
Part D cost-sharing.
Effective January 1, 2005,
the issuance of any of the
old standardized policies
with drug coverage would
be prohibited.  The bill
The three of the 10
standardized Medigap
plans offering drug
coverage would have to be
revised to complement, not
duplicate, Part D.  The
revised drug packages
could not offer coverage
for more than 90% of the
Part D cost-sharing.
Effective January 1, 2005,
the issuance of any of the
old standardized policies
with drug coverage would
be prohibited.  The bill
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to core benefits):  1)
coverage of 50% of the
cost-sharing otherwise
a p p l i c a b l e  ( e x c e p t
coverage of 100% cost-
sharing applicable for
preventive benefits); 2) no
coverage of the Part B
deductible; 3) coverage of
all hospital coinsurance for
long stays (as in current
core package); and 4) a
limitation on annual out-
of-pocket costs of $4,000
in 2005 (increased in
future years by an
appropriate inflation
adjustment as specified by
the Secretary).  The second
new policy would have the
same benefit structure as
the first new policy, except
that:  1) coverage would be
provided for 75%, rather
than 50%, of cost-sharing
otherwise applicable; and
2) the limitation on out-of-
pocket costs would be
$2,000, rather than $4,000.
Both policies could
provide for coverage of
Part D cost-sharing;
however, neither policy
could cover the Part D
deductible.  The bill would
require plans to sell any of
would guarantee issuance,
d u r i n g  t h e  p e r i o d
es tab l i shed  b y the
Secretary for Part D
enrollment, of the benefit
package the Secretary
d e t e r m i n e d  m o s t
comparable to the old
standardized drug policy
held by the policyholder.
would guarantee issuance,
d u r i n g  t h e  p e r i o d
es t ab l i shed  by the
Secretary for Part D
enrollment, of the benefit
package the Secretary
d e t e r m i n e d  m o s t
comparable to the old
standardized drug policy
held by the policyholder.
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the Plans A through Plan
G to individuals who
enroll in Part D within 63
days and who were
covered until then by
Medigap policy H, I, or J.
Drug Card
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require the Secretary to
endorse prescription drug
discount programs meeting
certain requirements and to
m a k e  a v a i l a b l e
information on such
programs to beneficiaries.
The program:  1) would
have to pass on to
enrollees discounts on
drugs, including discounts
n e g o t i a t e d  w i t h
manufacturers; 2)could not
be limited to mail order
drugs; 3) would have to
provide pharmaceutical
support services, such as
education and counseling,
and services to prevent
adverse drug interactions;
4) would have to provide
information to enrollees
t h a t  t he  Sec re t a ry
identified as being
No provision No provision No provision No provision
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would have to safeguard
individually identifiable
information in accordance
with the Health Insurance
P o r t a b i l i t y  a n d
a c c o u n t a b i l i t y  A c t
(HIPAA); and 6) would
have to meet requirements
the Secretary found
necessary to participate in
the transitional low-
income assistance program
(see below).  A beneficiary
could only be enrolled in
one endorsed program at a
time.  Annual enrollment
fees could not exceed $25.
Transitional Low-Income
Assistance Program
The bill would provide for
the implementation of a
transitional prescription
drug assistance program,
until the Part D program
was implemented, for
Medicare beneficiaries
with incomes under 175%
of poverty who did not




care programs under the
Department of Defense,
No provision No provision No provision No provision
CRS-31
Provisions H. R. 4954 H.R. 5019 (Rangel et al.) S. 2729 (Grassley et al.) S.Amdt. 4309 (Graham et al.)
S.Amdt. 4345
(Graham-Smith et al.) 
Veterans Administration,
Federal Employees Health
Benefits program, or the
Indian Health Care
I m p r o v e m e n t  A c t .
Individuals eligible for
assistance would have to
be enrolled under a
prescription drug discount
card program (or an
alternative state program
a p p r o v e d  b y  t h e
Secretary).  Appropriations
totaling $300 million in
FY2003, $2.1 billion in
FY2004, and $500 million
in FY2005 would be
available.  Funds would be
allotted among the states
based on the proportion of
Medicare beneficiaries
with incomes below 175%
of poverty.  The assistance
would be in the form of a
discount in addition to that
available under the
discount card program.
States could continue to
provide assistance under
their own pharmaceutical
assistance programs.
